Abstract A063: Exploring metabolic and liver steatosis comorbidities among Asian Americans with chronic Hepatitis B using All of Us research program datasets
Authors: Dong Lena , Le Han , Gong Olivia , Lu Wenyue , Ma Xiaoli , Pan Chun , Ma Grace X. , Zhu Lin 
Published: September 2024

Introduction: Metabolic abnormalities and hepatic steatosis are increasingly significant risk factors for liver cancer in Asia and worldwide, as the incidence of obesity and Type 2 diabetes rise. Previous data from Asian countries indicate varying prevalence rates of epidemiology of metabolic syndrome (MetS) and metabolic dysfunction-associated steatotic liver disease (MASLD) in CHB patients. Methods: This study aims to investigate the epidemiology of MetS and MASLD and their association with liver histology and hepatitis B virus (HBV) biomarkers in Asian Americans (AAs) with CHB. We used the AoU Research Program which contains 14,162 AAs in the Controlled Tier Dataset v7 and we created a cohort containing 274 (1.93%) AAs with CHB. Results: Of the 274 AAs, 48 (17.52%) have type-2 diabetes, 41 (14.96%) have obesity, 75 (27.37%) have high cholesterol, 97 (35.40%) have hypertension, and 49 (17.88%) have liver steatosis. MASLD is characterized by having liver steatosis along with at least one component of the MetS. Based on the definition, there are 46 individuals classified as having MASLD, which was 16.79% of all AAs with CHB. The high prevalence indicates that liver steatosis may be a significant risk factor for the development of MASLD in this population. Currently, we are still analyzing the data to examine the relationship and impact of MetS, MASLD, and other relevant factors. In this presentation, we will share our experience in utilizing the AoU datasets and discuss our next steps and timeline. In this presentation, we will also share our experience navigating the Researcher Workbench for data cleaning and analysis for our current NCI/NIH-funded projects that focuses on examining the metabolic and steatotic profile and risk factors among Asian Americans living with chronic hepatitis B. Conclusion: While the AoU Research Program offers unprecedented access to electronic health records, the dataset has proven challenging to work with. Addressing the remaining challenges entails several key aspects. Firstly, it involves the meticulous task of accounting for single-concept variables sourced from diverse origins. Secondly, there's the crucial step of synthesizing variables that essentially gauge identical concepts. Additionally, it requires a deep comprehension of the data structure and hierarchy, particularly when coding for disease presence. Equally vital is ensuring data accuracy and reliability throughout the process. Finally, we'll delve into previous setbacks, elucidating the solutions we've since devised. Through this presentation, we hope to facilitate communication and build connection with researchers in cancer health disparities field.

Citation Format: Lena Dong, Han Le, Olivia Gong, Wenyue Lu, Xiaoli Ma, Chun Pan, Grace X. Ma, Lin Zhu. Exploring metabolic and liver steatosis comorbidities among Asian Americans with chronic Hepatitis B using All of Us research program datasets [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr A063.